“52-Week Safety and Efficacy of Amlitelimab in Participants with Moderate-to-Severe Atopic Dermatitis: Preliminary Analysis from the Open-Label Long-Term ATLANTIS Trial”, J of Skin, vol. 10, no. 3, p. s780, May 2026, doi: 10.25251/nt8d2g73.